fbpx

Top 6 business priorities for the newly appointed Minister of Health

20/ 05/ 2021
  On May 20, the Verkhovna Rada appointed Viktor Liashko as the new Minister of Health. The European Business Association congratulates Mr. Liashko on his appointment and hopes for fruitful and effective cooperation in building a strong healthcare system in the country. We also wish the Minister much inspiration in such interesting but difficult work. The EBA community indicates 6 priority steps that business expects from the new Minister. First is continuing and further intensification of work on overcoming the COVID-19 pandemic. In this context, it is critical to ensure that all citizens of Ukraine have access to the COVID-19 vaccine as soon as possible. This will require the coordinated work of the Ministry of Health of Ukraine, the Verkhovna Rada, and the pharmaceutical community, namely, in continuing the improvement of the current legal regulation accordingly to such challenges. Second is defining a clear strategy and plan for implementing the next steps in reforming Ukraines health care system, including at the level of secondary (specialized) and tertiary (highly specialized) medical care, further expanding the program of medical guarantees and reimbursements, taking into account modern approaches to the treatment of relevant diseases in the countries that Ukraine has identified as a reference; preventing the deterioration in the quality of medical services due to the inability to purchase the necessary drugs within the program of medical guarantees. Third is harmonizing Ukrainian legislation with EU legislation in the field of pharmaceuticals, medical devices, and clinical research, as well as ensuring the effective implementation of new practices for Ukraine - in particular, continuing to implement the medical technology assessment (MTA), creating an independent MTA Agency, assisting the completion of the optimal regulatory framework for the implementation of managed entry agreements, introducing positive list of drugs, introducing gradual 2D-code individual labeling with the use of EU experience. Fourth is digitalizing the health and pharmaceutical sectors to improve health care delivery, as well as discussing with business on drug registration, certification, and control procedures, primarily through the introduction of an eCTD registration format for drug and clinical trials materials. Fifth is intensifying cooperation with the business community to address pressing issues in the functioning of the pharmaceutical industry that have a direct impact on providing patients with the necessary treatment in Ukraine, first of all, the critical problem with the confirmation of good manufacturing practice (GMP), which the EBA emphasized earlier, as well as the need to implement the optimal model in Ukraine given the coexistence of currently duplicate systems of state quality control of medicines at import and licensing of importers. Sixth is intensifying the work and cooperation with business on industrial issues, such as completion of amendments to MoH Order №2646 on residues of veterinary drugs, which will enable the re-registration of coccidiostats, harmonization of national legislation on baby foods with EU legislation, resolution of the enteral nutrition problem, etc. We hope for quality dialogue and look forward to meeting the newly appointed Minister promptly.   Be the first to learn about the latest EBA news with our Telegram-channel – EBAUkraine.

On May 20, the Verkhovna Rada appointed Viktor Liashko as the new Minister of Health. The European Business Association congratulates Mr. Liashko on his appointment and hopes for fruitful and effective cooperation in building a strong healthcare system in the country. We also wish the Minister much inspiration in such interesting but difficult work.

The EBA community indicates 6 priority steps that business expects from the new Minister.

First is continuing and further intensification of work on overcoming the COVID-19 pandemic. In this context, it is critical to ensure that all citizens of Ukraine have access to the COVID-19 vaccine as soon as possible. This will require the coordinated work of the Ministry of Health of Ukraine, the Verkhovna Rada, and the pharmaceutical community, namely, in continuing the improvement of the current legal regulation accordingly to such challenges.

Second is defining a clear strategy and plan for implementing the next steps in reforming Ukraine’s health care system, including at the level of secondary (specialized) and tertiary (highly specialized) medical care, further expanding the program of medical guarantees and reimbursements, taking into account modern approaches to the treatment of relevant diseases in the countries that Ukraine has identified as a reference; preventing the deterioration in the quality of medical services due to the inability to purchase the necessary drugs within the program of medical guarantees.

Third is harmonizing Ukrainian legislation with EU legislation in the field of pharmaceuticals, medical devices, and clinical research, as well as ensuring the effective implementation of new practices for Ukraine – in particular, continuing to implement the medical technology assessment (MTA), creating an independent MTA Agency, assisting the completion of the optimal regulatory framework for the implementation of managed entry agreements, introducing “positive list” of drugs, introducing gradual 2D-code individual labeling with the use of EU experience.

Fourth is digitalizing the health and pharmaceutical sectors to improve health care delivery, as well as discussing with business on drug registration, certification, and control procedures, primarily through the introduction of an eCTD registration format for drug and clinical trials materials.

Fifth is intensifying cooperation with the business community to address pressing issues in the functioning of the pharmaceutical industry that have a direct impact on providing patients with the necessary treatment in Ukraine, first of all, the critical problem with the confirmation of good manufacturing practice (GMP), which the EBA emphasized earlier, as well as the need to implement the optimal model in Ukraine given the coexistence of currently duplicate systems of state quality control of medicines at import and licensing of importers.

Sixth is intensifying the work and cooperation with business on industrial issues, such as completion of amendments to MoH Order №2646 on residues of veterinary drugs, which will enable the re-registration of coccidiostats, harmonization of national legislation on baby foods with EU legislation, resolution of the enteral nutrition problem, etc.

We hope for quality dialogue and look forward to meeting the newly appointed Minister promptly.

 

Be the first to learn about the latest EBA news with our Telegram-channel EBAUkraine.

If you have found a spelling error, please, notify us by selecting that text and pressing Ctrl+Enter.

Start
in the Telegram bot
Read articles. Share in social networks
0 Shares

Spelling error report

The following text will be sent to our editors: